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1644Background: Intra-airway and intra-arterial administration of gelatin-embedded, sustained-release basic
fibroblast growth factor has stimulated regeneration of emphysematous lungs in animal experiments, but these
routes of administration may also cause harm. This study investigated the effectiveness of intrapleural
administration of gelatin-embedded, sustained-release basic fibroblast growth factor. This animal experiment
preceded our clinical trial of intrapleural administration of sustained-release basic fibroblast growth factor in
patients with chronic obstructive pulmonary disease accompanied by pneumothorax.
Methods: Pulmonary emphysema was induced in Sprague-Dawley rats using porcine elastase. Gelatin-
embedded, sustained-release basic fibroblast growth factor was administered via the left pleural cavity. The
rats were divided into a group that received gelatin-embedded, sustained-release basic fibroblast growth factor
(FGFþ group, n¼ 6), and a group that did not (FGF–group, n¼ 6). Animals were sacrificed after 14 days, and the
results were evaluated by histologic examination.
Results: In the FGFþ group, the mean linear intercept value of the alveolar septa was significantly shorter on
the treated side than on the untreated side (65.1  7.0 vs 114.4  7.5 mm; P ¼ .0005). There was no significant
difference in the mean linear intercept value between the treated and untreated sides in the FGF group.
Conclusions: Intrapleural administration of sustained-release basic fibroblast growth factor induced lung
regeneration in rats with elastase-induced pulmonary emphysema. (J Thorac Cardiovasc Surg 2014;147:1644-9)Pulmonary emphysema is characterized by permanent
abnormal enlargement of the air spaces distal to the terminal
bronchioles, with destruction of the terminal bronchiolar
walls but no obvious fibrosis.1 Although medications and
home oxygen therapy can help to control symptoms,
there is no treatment available to reverse the changes in
pulmonary structure, and the prognosis of patients with
emphysema is, therefore, extremely poor.
Surgical treatments may improve pulmonary function,
but they have disadvantages. Lung transplantation is the
most effective treatment, but it is difficult because of a
shortage of donors, the need for immunosuppression, and
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The Journal of Thoracic and Cardiovascular Surreduction surgery has failed to show a survival benefit.3 If
regeneration of emphysematous lung tissue can be induced,
this could provide a promising option for the treatment of
pulmonary emphysema.
Regeneration of emphysematous lung tissue has already
been reported in animal experiments.4-9 In 2005, Morino
and colleagues8 reported that intra-alveolar administration
of gelatin-embedded, sustained-release (SR) basic fibro-
blast growth factor (bFGF) induced regeneration of alveolar
structure in an experimental canine emphysema model.
In 2008, Mori and colleagues9 also reported pulmonary
regeneration after administration of SR-bFGF via the
pulmonary artery in a canine emphysema model.
SR-bFGF appears to be a promising treatment for
the regeneration of emphysematous lungs. However,
intra-airway or intra-arterial administration of the gelatin
hydrogel, rather than bFGF solution, may be harmful to
patients. The administration of gelatin hydrogel may cause
temporary deterioration in pulmonary function because of
atelectasis or pulmonary embolism.8,9 We believe that this
obstacle to the clinical use of SR-bFGF in patients with
pulmonary emphysema can be overcome by using an
alternative route of administration.
Patients with severe pulmonary emphysema often
develop pneumothorax.10 Most of these patients have
intractable disease because of severe destruction of thegery c May 2014
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bFGF ¼ basic fibroblast growth factor
FGF ¼ fibroblast growth factor
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Kawago et al Evolving Technology/Basic Sciencelung parenchyma. We previously reported intrapleural
administration of large amounts of diluted fibrin glue for
the treatment of intractable pneumothorax.11 Diluted fibrin
glue is easily introduced into the pleural cavity via a
drainage tube, and can be distributed throughout the pleural
space. This procedure is widely used in patients with
high-risk pneumothorax.12,13
We planned intrapleural administration of SR-bFGF
in patients with pneumothorax who were undergoing
intrapleural administration of a large amount of diluted
fibrin glue. By adding SR-bFGF to the diluted fibrin glue,
SR-bFGF can easily be delivered to the entire pleural
surface of the affected lung. We speculate that this route
of administration will not harm our patients and may,
therefore, open the door to regeneration therapy in patients
with pulmonary emphysema. However, there are no reports
describing the effectiveness of intrapleural administration of
SR-bFGF in terms of regeneration of emphysematous lungs.
In this study, we investigated the effectiveness of
intrapleural administration of SR-bFGF in an animal model
of elastase-induced pulmonary emphysema. This study
preceded our clinical trial of intrapleural administration of
SR-bFGF in patients with pulmonary emphysema.E
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Preparation of the Elastase-Induced Rat Pulmonary
Emphysema Model
The study design was approved by the animal experiment ethical review
board of our institute (No. 363). The experiments were performed in
accordance with the Guide for the Care and Use of Laboratory Animals.14
Eighteen 14-week-old female Sprague-Dawley rats were used. The animals
were divided into 4 groups: the completely untreated group (untreated
group, n ¼ 2), the elastase-only group (n ¼ 2), the group that received
SR-bFGF (FGFþ group, n ¼ 7), and the group that received gelatin
hydrogel without bFGF (FGF group, n ¼ 7). Animals in the untreated
group were used to obtain histologic findings of normal lungs, and were
observed for 10 weeks without undergoing any experimental procedures.
Sixteen rats were anesthetized by isoflurane inhalation with spontaneous
breathing. The skin over the ventral aspect of the neckwas incised, and the tra-
cheawas exposed. A 26-gauge needle was used to inject 250 U (total volume,
500 mL) of porcine elastase (Nacalai Tesque, Kyoto, Japan) into the trachea.
The neck skin was sutured closed, and the rats were rotated several times to
distribute the elastase solution equally to both lungs. The rats were then
observed for 8 weeks while they developed pulmonary emphysema.15 Deve-
lopment of pulmonary emphysema was confirmed by the preliminary study.
Preparation of SR-bFGF
Gelatin was isolated from bovine bone collagen by an alkaline process
using CaOH2 (Nitta Gelatin Company, Osaka, Japan). Gelatin hydrogelThe Journal of Thoracic and Carsheets were prepared by glutaraldehyde cross-linking of gelatin, as
previously described.16 The sheets were crushed into small particles, and
particles smaller than 53 mm in diameter were collected using a mesh filter.
The gelatin hydrogel particles were freeze dried and sterilized using
ethylene oxide.
Human recombinant bFGF (Kaken Pharmaceutical Co, Tokyo, Japan)
was incorporated into the gelatin hydrogel particles just before the
experiment. For each rat, 200 mg of bFGF diluted in 20 mL of saline was
combined with 20 mg of freeze-dried gelatin hydrogel particles, followed
by incubation for 1 hour at room temperature. Gelatin hydrogel particles
combined with 20 mL of saline but no bFGFwere also prepared as a control.
The gelatin hydrogel particles were mixed with 500 mL of fibrin glue
solution (Beriplast P Combi-Set; CSL Behring, Tokyo) just before
administration.
Intrapleural Administration of SR-bFGF
At 8 weeks after intra-airway administration of porcine elastase, 14 of
the 16 elastase-treated rats were reanesthetized. The other 2 rats were
not reanesthetized (the elastase-only group). A small skin incision was
made on the left side of the chest, the intercostal muscles were incised,
and diluted fibrin glue containing gelatin hydrogel particles was adminis-
tered via the left pleural cavity. The incisions were closed as quickly as
possible, and the rats were manually rotated several times to distribute
the gelatin hydrogel particles throughout the pleural cavity. Seven rats
received gelatin hydrogel particles with bFGF (FGFþ group), and the other
seven received gelatin hydrogel particles without bFGF (FGF group).
Histologic Examination
All rats were sacrificed at 14 days after the administration of gelatin
hydrogel particles, including the rats in the untreated and elastase-only
groups. All animals were sacrificed under deep anesthesia using isoflurane.
Both lungs and the trachea were excised en bloc. The lungs were immedia-
tely fixed in 4% buffered formalin at a constant airway pressure of 20 cm
H2O for 1 week. Both lungs were then cut into sagittal slices and embedded
in paraffin. The paraffin blocks were cut into 3-mm-thick sections and
stainedwith hematoxylin and eosin. Themean linear intercept (LM), which
is the standard technique for measuring the size of alveolar spaces,17 was
used to evaluate the effectiveness of SR-bFGF treatment. The measuring
methods for LM were essentially identical as previously reported. In this
study, lung slices were observed at 3100 magnification. Photographs of
2776 pixels wide were taken at the upper quarter, center, and lower quarter
of thewhole lung sagittal section. LMs of 3 horizontal lines were calculated
and averaged in each photograph. Then, the median value of LM was
adopted in each lung.
Statistical Analysis
Data are expressed as means and SDs. Differences between groups were
analyzed using the unpaired t-test. Differences between the right and left
lungs were analyzed using the paired t-test. P < .05 was considered
statistically significant.RESULTS
A microscopic examination showed severe destruction
of the alveolar walls at 10 weeks after intra-airway
injection of porcine elastase (Figure 1). The mean LM
was approximately twice as long in the elastase-only group
as in the untreated group (116.4  19.5 vs 54.5  3.8 mm;
P<.0001).
Figure 2 shows the typical microscopic findings of lung
tissue after administration of gelatin hydrogel particles. In
the FGF group, the severity of alveolar wall destructiondiovascular Surgery c Volume 147, Number 5 1645
FIGURE 1. Microscopic findings of lung sections. A, Normal lung (untreated group). The mean linear intercept of this section was 57.7 mm.
B, Ten weeks after administration of porcine elastase (elastase-only group). The mean linear intercept of this section was 121.7 mm. Hematoxylin and eosin
staining, 3100.
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left lung (Figure 2, B). In the FGFþ group, alveolar wall
destruction appears to be more severe in the right lung
(Figure 2, C) than in the left lung (Figure 2, D).
The LMs of the lungs in each group are shown in
Figure 3. In the FGF group, there was no significant
difference in mean LM between the right and left lungsFIGURE 2. Representative microscopic findings of the lung sections of rats wh
factor (FGF) group. B, Left lung in the FGF group. C, Right lung in the FGF
3100. The mean linear intercepts in these sections were 109.2 mm in A, 122.7
1646 The Journal of Thoracic and Cardiovascular Sur(119.3  23.2 vs 115.0  14.3 mm; P ¼ .6237). In the
FGFþ group, the mean LM was significantly longer in
the right lung than in the left lung (114.4  17.5 vs
65.1  7.0 mm; P ¼ .0005). The mean LM of the left
lung was also significantly shorter in the FGFþ group
than in the FGF group (P< .0001). However, the mean
LM was still significantly longer in the left lung of theo received gelatin hydrogel particles. A, Right lung in the fibroblast growth
þ group. D, Left lung in the FGFþ group. Hematoxylin and eosin staining,
mm in B, 109.9 mm in C, and 67.1 mm in D.
gery c May 2014
FIGURE 3. Mean linear intercepts of the lung sections of rats that
received gelatin hydrogel particles. b-FGF, Basic fibroblast growth factor.
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was no significant difference in the mean LM of the right
lung between the FGF and FGFþ groups (P ¼ .4875).
DISCUSSION
Many researchers have tried to find treatments that can
induce regeneration of damaged alveoli. In vivo animal
experiments found that administration of stem cells,
retinoic acids, hepatocyte growth factor, adrenomedullin,
and bFGF has the potential to induce lung regeneration.4-9
Only 2 clinical trials have reported on regeneration of
damaged alveoli in patients with pulmonary emphysema.
In 2012, Stolk and colleagues18 reported the results of a
randomized controlled trial of the g-selective retinoic acid
agonist, palovarotene, in 262 patients with pulmonary
emphysema. However, they did not find any evidence of
lung regeneration in these patients. Weiss and colleagues19
reported the results of a randomized controlled trial of
allogeneic mesenchymal stem cell administration in
patients with pulmonary emphysema. This therapy was
reported to be safe, but did not result in lung regeneration.
To date, no effective lung regeneration therapy for patients
with pulmonary emphysema has been reported.
bFGF is a single-chain polypeptide growth factor that
plays a significant role in the process of wound healing. It
acts as a strong angiogenic factor that stimulates smooth
muscle cell growth, wound healing, and tissue repair.9 It
is also known to play a role in the development of the fetal
lung.20,21 bFGF has been used to treat chronic skin wounds,
such as pressure ulcers, since 2001, and its effectiveness and
safety profile for this use are well known.22,23 The biologic
half-life of bFGF is less than 50 minutes,24 which is too
short for a single topical administration to be sufficient,
because wound healing processes take longer than a
day.25 Therefore, administration at least once a day is
recommended for the treatment of skin ulcers.The Journal of Thoracic and CarRepeated daily topical administration of bFGF for organ
regeneration therapy is almost impossible. Conjugation
with a sustained-release material is, therefore, necessary.
When SR-bFGF is administered, the bFGF is released
slowly as the gelatin hydrogels degrade. The rate of
degradation is controlled by the conditions of the cross-
link reaction. Our previous experiment found that gelatin
hydrogels remained for more than 14 days after administra-
tion.16 Previous clinical trials reported that SR-bFGF was
useful and safe for the treatment of bone fractures, skin
defects, and peripheral arterial disease.26-29
We believe that SR-bFGF is the most promising potential
treatment for inducing lung regeneration in patients with
pulmonary emphysema.We speculate that finding a suitable
route of administration is the only obstacle to SR-bFGF
treatment for pulmonary emphysema. Administration of
SR-bFGF via the intrapleural cavity easily overcomes this
obstacle. Patients with intractable pneumothorax already
have thoracic drains, and administration of SR-bFGF
together with intrapleural administration of diluted fibrin
glue does not cause any additional harm.
We were unsure whether intrapleural administration
of SR-bFGF would result in regeneration of damaged
alveoli in emphysematous lungs, as with intra-airway or
intra-arterial administration. We, therefore, conducted this
animal experiment before starting a clinical trial. There
were no unexpected deaths during the experiment, and it
appears that intrapleural administration of SR-bFGF is a
safe procedure.
Our results show that the mean LM was significantly
shorter in the left lung than the right lung in the FGFþ
group, indicating that intrapleural administration of
SR-bFGF can induce lung regeneration in an elastase-
induced pulmonary emphysema model. The definition of
LM indicates that the square of LM is inversely proportional
to the number of alveoli. Therefore, our results show that
the lungs had 3.2 times as many alveoli after SR-bFGF
treatment as before treatment. The mean LM was longer
in the left lung of the FGFþ group than in the normal
control group, indicating that recovery was incomplete.
After SR-bFGF administration, the treated lungs had
approximately 70% of the normal number of alveoli.
These results were not inferior to those of intra-airway
and intra-arterial administration.
The precise mechanism of lung regeneration by SR-
bFGF is not proved. This study was not designed to prove
it. However, Morino et al.8 have already mentioned the
detailed speculation in their report. bFGF is one of the
most powerful angiogenic factors and is indispensable
for lung development and branching morphogenesis.
SR-bFGF might act in the same mechanism as lung
development in the fetal stage.21,30 They also noticed that
bFGF alone can not develop the lung regeneration. They
also speculated that the powerful angiogenic effect ofdiovascular Surgery c Volume 147, Number 5 1647
FIGURE 4. Microscopic findings of lung sections of the right lung
(A) and left lung (B) in the same rat at low magnification (320).
Left side of the photo is the subpleural region and right side is the center
of the lung. Lung regeneration appeared to occur in the center of the
lung and the subpleural area.
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blood flow caused by SR-bFGF enables to supply
sufficient dose of various biological substances that are
necessary in the lung regeneration to the parenchyma of
the emphysematous lung. There might be another possible
explanation in the mechanism of lung regeneration.
Pulmonary emphysema is the destruction of the lung
parenchyma. bFGF has the strong effect to promote wound
healing. Our data might be the result of an accelerated
wound healing process.
At the beginning of the study, we were afraid that the
regeneration might occur only in a subpleural lesion.
Against expectations, the regeneration effects did not look
heterogeneous among whole lung (Figure 4). However, rat
lung is smaller than human lung. The effect of SR-bFGF
might be more limited in the clinical application.
In rats treated with SR-bFGF, the mean LM of the right
lung was the same as the mean LM in the FGF group,
indicating that intrapleural administration did not result in
recovery of the contralateral lung. However, we believe
that the results of this study provided sufficient evidence
to start our clinical trial, and we have commenced the
‘‘Intrapleural Administration of Sustained-Release Basic
Fibroblast Growth Factor in Patients with Chronic Obstruc-
tive Pulmonary Disease Accompanied by Pneumothorax:
UMIN000004276’’ trial at our institute.
CONCLUSIONS
Intrapleural administration of SR-bFGF induced lung
regeneration in an elastase-induced pulmonary emphysema
model in rats.
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